CD_(40)在胃癌中的研究进展  

The Research Progress of CD_(40) in Gastric Cancer

作　　者：何玉龙[1] 陈琳[1] 

机构地区：[1]广西壮族自治区人民医院化疗二区,南宁530021

出　　处：《医学综述》2011年第17期2607-2610,共4页Medical Recapitulate

摘　　要：CD40是肿瘤坏死因子受体超家族成员之一,与其配体CD40L结合,参与细胞免疫及体液免疫,而且还可起到直接的治疗作用。CD40在胃癌患者中也有不同程度的表达,与胃癌的侵袭、转移等生物学行为相关,参与胃癌的发生发展。CD40信号的激发能增加胃癌细胞株对化疗的敏感性,甚至促进其凋亡。鉴于此,人们基于CD40的肿瘤疫苗、单克隆抗体、小分子化合物等胃癌生物治疗手段开展了广泛研究。CD40 is a member of tumor necrosis factor receptor superfamily, CD40 ligation by C D40 L participate in the cellular immune and humoral immune, and has direct therapeutical effect.In patients with gastric cancer, CD40 also has different degrees of expression, and is correlated with bioactivities such as invasion and metastasis, playing an important role in the development of tumor. The stimulation of CD40 signal can increase the sensitivity of gastric cancer cell lines to chemotherapy and even promote the apoptosis. In view of this, the studies of biotherapy, such as cancer vaccine, monoclonal antibodies, small molecules compound based on CD40 ,were carried out widely.

关 键 词：CD40 胃肿瘤 生物治疗 

分 类 号：R735.2[医药卫生—肿瘤]